Skin Cancer & Melanoma Clinical Trials

UCI 09-17  
Biology of Human Melanocytes and Keratinocytes (Meyskens)

UCI 14-25  
Plasma Exosome Concentration in Cancer Patients Undergoing Treatment (Nelson)

UCI 16-01  
(PAINT)-Pathway Analyses for Individualized Network Therapeutics for Cancer (Nelson)

Prevention  
UCI 14-92  
Phase IV Study of Daylight Photodynamic Therapy with Aminolevulinic Acid for Actinic Keratoses (Zachary)

Screening/Diagnostic  
UCI 11-30  
Skin imaging with Technologies in Development (Kelly)

UCI 14-05  
Multi-Center Evaluation of Oncogenesis via Spectral Analysis with the Melanoma Advanced Imaging Dermascope (mAID) (Linden/Kelly)

UCI 13-13  
Pilot study on in-vivo non-invasive skin imaging using multiphoton microscopy and multispectral imaging (Kelly)

UCI 15-08  
Spectral comparison between Spatially Modulated Quantitative Spectroscopy (SMoQS) and Polarization Sensitive Hyperspectral Multimode Dermoscopy for the purpose of skin compositional analysis (Kelly)

UCI 16-82  
DecisionDx-Melanoma 31-Gene Expression Profile Clinical Impact Study #4

UCI 16-37**  
Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome (Pinter-Brown)

UCI 16-95  
Epidemiologic/Correlative

Therapeutic  
UCI 16-96  
Ph I Study of RET Inhibitor, BLU-667, in Patients w/ Thyroid Cancer, NSCLC & Other Adv Solid Tumors (Ou)

UCI 16-45  
Ph I/II Safety & Efficacy Study of RP6530, a Dual PI3K ë/ï inhibitor, for Relapsed/Refractory TCL (Pinter-Brown)

UCI 16-46  
Ph I MRG-106 Safety/Tolerability/Pks Study After Intratumoral/Subcutaneous/IV Injection for CTCL, MF (Pinter-Brown)

ECOG-EAY131  
Molecular Analysis for Therapy Choice (MATCH) (Seery)

UCI 16-92  
Ph III Study of Atezo+Cobi+Vem vs Placebo+Cobi+Vem in Prev Untreated BRAFV600 Pos Melanoma (Fruehauf)

UCI 16-102**  
A Phase III, Open-Label, Multicenter, Two Arm, Randomized Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab versus Pembrolizumab in Patients with Previously Untreated Advanced BRAFV600 Wild-Type Melanoma (Fruehauf)

UCI 16-09**  
A Randomized, Double-Blind, Placebo-Controlled, Phase III Study Comparing the Combination of PDR001, Dabrafenib and Trametinib versus Placebo, Dabrafenib and Trametinib in Previously Untreated Patients with Unresectable or Metastatic BRAF V600 Mutant Melanoma (Fruehauf)

UCI 17-73**  
Effects of Encorafenib w/ Binimetinib on Losartan/etc Cocktail and on Rosuvastatin in BRAF V600-mut (Fruehauf)

SWOG S1609  
(CIRB) DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (Bota)

UCI 17-50**  
A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-399, an Antibody Drug Conjugate, in Subjects with Advanced Solid Tumors (Ou)

UCI 17-58**  
Phase 1-2 Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX660 in Subjects with Advanced Solid Tumors and Lymphomas (Pinter-Brown)

For more details contact 1-877-UC-STUDY OR ucstudy@uci.edu

**Opening soon